153808-85-6|Cadrofloxacin|(S)-1-cyclopropyl-8-(difluoromethoxy)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid|-范德生物科技公司

Cadrofloxacin

NMR下载 COA and HPLC MSDS下载
names：
(S)-1-cyclopropyl-8-(difluoromethoxy)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
CAS号：
153808-85-6
MDL Number：
MF(分子式)： C19H20F3N3O4 MW(分子量)： 411.3812
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Cadrofloxacin
英文别名	CS-940; CS 940; CS940; Cadrofloxacin; Caderofloxacin; Cadrofloxacin hydrochloride; Cadrofloxacin HCl.
CAS号	153808-85-6
SMILES	O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4C[C@H](C)NCC4)=C3OC(F)F)C1=O)O
Inchi	InChI=1S/C19H20F3N3O4/c1-9-7-24(5-4-23-9)15-13(20)6-11-14(17(15)29-19(21)22)25(10-2-3-10)8-12(16(11)26)18(27)28/h6,8-10,19,23H,2-5,7H2,1H3,(H,27,28)/t9-/m0/s1
InchiKey	QBDBUKJBJJWZMG-VIFPVBQESA-N
分子式 Formula	C19H20F3N3O4
分子量 Molecular Weight	411.3812
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Cadrofloxacin(CAS:153808-85-6 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Cadrofloxacin, also known as Caderofloxacin and CS-940, is a novel fluoroquinolone antibacterial. The activities of CS-940 against gram-positive cocci and gram-negative rods, including methicillin-susceptible Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, were comparable to those of tosufloxacin, with MICs at which 90% of the strains were inhibited (MIC90s) of 0.5 microg/ml or less. Against methicillin-resistant S. aureus, CS-940 was as active as tosufloxacin, with a MIC90 of 16 microg/ml. The efficacy of CS-940 against murine respiratory infections due to S. pneumoniae or Haemophilus influenzae was better than those of tosufloxacin and sparfloxacin. The efficacy of oral doses of CS-940 reflected not only potent in vitro activity but also a high transmigration ratio from the bloodstream to lung tissues.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Ma RL, Zhou HH, Liu R, Wang EH, Sheng LS. [Analysis of impurity in caderofloxacin]. Yao Xue Xue Bao. 2003 Dec;38(12):950-2. Chinese. PubMed PMID: 15040093.

[2]Kawahara S, Tada A, Nagare H. [Clinical evaluation of new quinolones as antituberculosis drugs]. Kekkaku. 1999 Jan;74(1):71-5. Review. Japanese. PubMed PMID: 10067058.

[3] Namba K. [View of development of fluoroquinolones]. Kekkaku. 1999 Jan;74(1):47-52. Review. Japanese. PubMed PMID: 10067055.

[4] Kawahara S. [Chemotherapeutic agents under study]. Nihon Rinsho. 1998 Dec;56(12):3096-9. Review. Japanese. PubMed PMID: 9883617.

[5] Miyazaki S, Domon H, Tateda K, Ohno A, Ishii Y, Matsumoto T, Furuya N, Yamaguchi K. In vitro and in vivo antibacterial activities of CS-940, a new fluoroquinolone, against isolates from patients with respiratory infections. Antimicrob Agents Chemother. 1997 Nov;41(11):2582-5. PubMed PMID: 9371375; PubMed Central PMCID: PMC164170.

6: Schmitz FJ, Jones ME. Antibiotics for treatment of infections caused by MRSA and elimination of MRSA carriage. What are the choices? Int J Antimicrob Agents. 1997 Jun;9(1):1-19. PubMed PMID: 18611815.7: Mizutani S. [Chemotherapy of pulmonary Mycobacterium kansasii infection]. Kekkaku. 1996 Sep;71(9):527-31. Japanese. PubMed PMID: 8914388.8: Takenouchi T, Tabata F, Iwata Y, Hanzawa H, Sugawara M, Ohya S. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother. 1996 Aug;40(8):1835-42. PubMed PMID: 8843290; PubMed Central PMCID: PMC163426.9: Yamane N, Chilima BZ, Tosaka M, Okazawa Y, Tanno K. [Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media]. Kekkaku. 1996 Aug;71(8):453-8. Japanese. PubMed PMID: 8831190.10: Masuda N, Takahashi Y, Otsuki M, Ibuki E, Miyoshi H, Nishino T. In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone. Antimicrob Agents Chemother. 1996 May;40(5):1201-7. PubMed PMID: 8723467; PubMed Central PMCID: PMC163292.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开